Petrelintide (ZP8396) Amylin Analog

Petrelintide (ZP8396) is a long-acting amylin analog designed to improve solubility, minimize fibrillation, and allow for co-formulation with other peptides, including GLP-1-based molecules. ZP8396 holds potential as a next-generation treatment for overweight and obesity that could provide weight loss comparable with GLP-1-based therapies with improved tolerability.

Zealand is currently conducting a Phase 1b, randomized, multiple ascending dose (MAD) clinical trial of ZP8396 in normal weight and overweight healthy participants.